OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that HLH BioPharma Vertriebs GmbH have achieved product registration of LP(LDL) (R) capsules at IFA GmbH and “Bundesamt für Lebensmittelsicherheit und Verbraucherschutz (BVL)” and commenced commercial sales to pharmacies in Germany on 24 July 2017.
This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH announced on 15 June 2017. HLH will market capsules containing LP(LDL) (R) under the brand name Lactobact(R) LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform. Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to see the first sales of our LP(LDL) (R) strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LP(LDL) (R) as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe’s leading suppliers of probiotics to the pharmacy market. Establishing early sales of LP(LDL) (R) to pharmacies with HLH helps substantiate the credibility in the science behind LP(LDL) (R) to build the brand and acceptance in the larger consumer healthcare markets.”
